SEPTEMBER - 2023LIFE SCIENCES REVIEW6Next-generation sequencing (NGS) companies continue to refine and optimize their sequencing technology, improving accuracy, reducing error rates, and lowering sequencing costs. Increasingly complex and abundant sequencing data has necessitated the development of new bioinformatics tools and pipelines to handle large-scale data analysis, variant calling, and annotation tasks. NGS techniques help to gain insights that can be used for medical interventions. The NGS technology provides immense advantages in immunotherapy, creating unique, new medicines.The global next-generation sequencing market size is projected to reach $35,503.66 million by 2030 at a CAGR of 18.2 percent. Genome mapping programs, next-generation sequencing applications, healthcare expenditures, and technology advancements are significant drivers of the global next-generation sequencing market. Pharmaceutical drug discovery is greatly accelerated using NGS in pharmacogenomics, which propels market growth. Increased investment in NGS technologies worldwide has boosted R&D related to NGS to new heights, as the surge in demand and its application enables market growth.This edition of Life Sciences Review APAC brings forth the growing integration of genomic data with other omics data to better understand biological systems and diseases, with continuous technological advancements as healthcare organizations strive to stay at the forefront.It features a thought leadership article from TJ Bing, Head of Biology at ICE Bioscience Inc., who sheds light on how Next-generation sequencing plays a critical role in the research, allowing them to identify new markers or targets for further drug discovery efforts. It also features an article from Dr. Israfil Merican MD, MHM, Head of Medical Affairs at Pharmaniaga Berhad, who discusses the importance of clinical trials in the development of new medicines, including halal biosimilars for an alternative medicine that is insufficient as healthcare professionals hold dearly the evidence-based drugs in their practices. In this edition of Life Sciences Review APAC, we also bring you the story of some of the top Next-generation sequencing solution providers that cater to delivering disruptive technologies of NGS-based diagnostic tests for prevalent clinical practice. One of them is Personal Genomics, a pre-commercial stage R&D company that aims to revolutionize DNA sequencing by developing a decentralized sequencing technology accessible to all laboratories in the life science industry. In this edition featuring the top Next-Generation Sequencing Solutions Providers in APAC 2023, we hope you find the right partner for your business requirements.Let us know your thoughts!EDITORIALNext-Generation Sequencing: Latest Clinical ApplicationsCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsSeptember - 04 - 2023, Vol 04, Issue - 38 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersPresley MeadowVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >